Endurance Wealth Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $21.8M | Sell |
231,099
-390
| -0.2% | -$33.9K | 2.98% | 6 |
|
|
2023
Q1 | $19.2M | Sell |
231,489
-670
| -0.3% | -$52.7K | 2.71% | 9 |
|
|
2022
Q4 | $17.3M | Sell |
232,159
-2,525
| -1% | -$195K | 2.61% | 8 |
|
|
2022
Q3 | $19.4M | Sell |
234,684
-719
| -0.3% | -$69.2K | 3.2% | 7 |
|
|
2022
Q2 | $22.4M | Sell |
235,403
-634
| -0.3% | -$65.6K | 3.4% | 5 |
|
|
2022
Q1 | $27.8M | Buy |
236,037
+5,973
| +3% | +$670K | 3.59% | 5 |
|
|
2021
Q4 | $29.8M | Sell |
230,064
-5,475
| -2% | -$639K | 3.21% | 5 |
|
|
2021
Q3 | $26.7M | Sell |
235,539
-4,277
| -2% | -$488K | 2.97% | 5 |
|
|
2021
Q2 | $24.8M | Sell |
239,816
-1,949
| -0.8% | -$184K | 2.75% | 7 |
|
|
2021
Q1 | $20.2M | Sell |
241,765
-1,216
| -0.5% | -$103K | 2.38% | 10 |
|
|
2020
Q4 | $22.2M | Sell |
242,981
-1,419
| -0.6% | -$118K | 2.8% | 6 |
|
|
2020
Q3 | $19.5M | Sell |
244,400
-3,605
| -1% | -$281K | 2.87% | 7 |
|
|
2020
Q2 | $17.1M | Sell |
248,005
-1,964
| -0.8% | -$140K | 2.81% | 8 |
|
|
2020
Q1 | $15.7M | Sell |
249,969
-1,917
| -0.8% | -$138K | 3.02% | 7 |
|
|
2019
Q4 | $19.6M | Sell |
251,886
-1,080
| -0.4% | -$84.3K | 3% | 6 |
|
|
2019
Q3 | $18.5M | Sell |
252,966
-12,372
| -5% | -$869K | 3.08% | 5 |
|
|
2019
Q2 | $16.3M | Sell |
265,338
-1,935
| -0.7% | -$117K | 2.57% | 7 |
|
|
2019
Q1 | $17M | Sell |
267,273
-5,286
| -2% | -$302K | 2.79% | 7 |
|
|
2018
Q4 | $13.9M | Sell |
272,559
-3,984
| -1% | -$202K | 2.59% | 7 |
|
|
2018
Q3 | $16M | Sell |
276,543
-6,894
| -2% | -$337K | 2.53% | 7 |
|
|
2018
Q2 | $13.8M | Sell |
283,437
-7,044
| -2% | -$329K | 2.27% | 8 |
|
|
2018
Q1 | $13.5M | Sell |
290,481
-4,953
| -2% | -$215K | 2.27% | 9 |
|
|
2017
Q4 | $11.1M | Buy |
295,434
+705
| +0.2% | +$25.9K | 1.78% | 17 |
|
|
2017
Q3 | $10.7M | Sell |
294,729
-2,640
| -0.9% | -$101K | 1.78% | 16 |
|
|
2017
Q2 | $11.7M | Buy |
297,369
+705
| +0.2% | +$25.7K | 1.98% | 11 |
|
|
2017
Q1 | $9.3M | Buy |
296,664
+8,925
| +3% | +$279K | 1.61% | 19 |
|
|
2016
Q4 | $8.99M | Buy |
287,739
+46,215
| +19% | +$1.5M | 1.61% | 20 |
|
|
2016
Q3 | $9.77M | Sell |
241,524
-750
| -0.3% | -$28.2K | 1.75% | 12 |
|
|
2016
Q2 | $8.05M | Buy |
242,274
+2,580
| +1% | +$88.3K | 1.51% | 19 |
|
|
2016
Q1 | $7.05K | Sell |
239,694
-5,442
| -2% | -$150K | 0.99% | 26 |
|
|
2015
Q4 | $6.45M | Sell |
245,136
-810
| -0.3% | -$21K | 1.23% | 30 |
|
|
2015
Q3 | $6.13M | Buy |
245,946
+12,474
| +5% | +$301K | 1.08% | 29 |
|
|
2015
Q2 | $5.54M | Buy |
233,472
+11,994
| +5% | +$271K | 0.93% | 33 |
|
|
2015
Q1 | $5.26M | Buy |
221,478
+6,864
| +3% | +$154K | 0.92% | 32 |
|
|
2014
Q4 | $4.56M | Buy |
214,614
+8,100
| +4% | +$163K | 0.82% | 36 |
|
|
2014
Q3 | $3.52M | Hold |
206,514
| – | – | 0.66% | 47 |
|
|
2014
Q2 | $2.95M | Buy |
+206,514
| New | +$2.8M | 0.49% | 57 |
|
Other funds holding EW
Endurance Wealth Management's EW Position: Q2 2023 in Review
Endurance Wealth Management reduced its Edwards Lifesciences (EW) stake by 0.17% in Q2 2023, selling an estimated $33.9K and leaving 231,099 shares worth $21.8M. The position accounts for 2.98% of the portfolio, ranked #6.
Endurance Wealth Management first reported a position in EW in Q2 2014 and has held it in 37 quarters since. The position peaked at $29.8M in Q4 2021. 1,279 funds tracked by Wall St. Rank hold EW as of Q2 2023.
- Endurance Wealth Management held 231,099 shares of Edwards Lifesciences worth $21.8M as of Q2 2023.
- Endurance Wealth Management sold 390 Edwards Lifesciences shares in Q2 2023, an estimated $33.9K.
- Edwards Lifesciences made up 2.98% of Endurance Wealth Management's portfolio in Q2 2023, its #6 holding.
- Endurance Wealth Management first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 37 quarters since.
- Endurance Wealth Management's Edwards Lifesciences position peaked at $29.8M in Q4 2021.
- 1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2023.
Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.